Delaware | 000-06920 | 94-1655526 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
3050 Bowers Avenue | ||
P.O. Box 58039 | ||
Santa Clara, CA | 95052-8039 | |
(Address of principal executive | (Zip Code) | |
offices) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition | ||||||||
Item 9.01 Financial Statements and Exhibits | ||||||||
SIGNATURES | ||||||||
EXHIBIT INDEX | ||||||||
EX-99.1 |
Exhibit No. | Description | |
99.1
|
Press Release issued by Applied Materials, Inc. dated February 10, 2009. |
Applied Materials, Inc. (Registrant) |
||||
Date: February 10, 2009 | By: | /s/ Joseph J. Sweeney | ||
Joseph J. Sweeney | ||||
Senior Vice President, General Counsel and Corporate Secretary |
Exhibit No. | Description | |
99.1
|
Press Release issued by Applied Materials, Inc. dated February 10, 2009. |
NEWS RELEASE | CONTACT: | |||
David Miller (editorial/media) 408.563.9582 | ||||
Michael Sullivan (financial community) 408.986.7977 |
Q1 FY 09 | Q1 FY 08 | Q4 FY 08 | ||||||||||
Net sales |
$1.33 billion | $2.09 billion | $2.04 billion | |||||||||
Gross margin percent |
29.4 | % | 44.8 | % | 39.1 | % | ||||||
Net income (loss) |
($133 million) | $262 million | $231 million | |||||||||
Earnings (loss) per share |
($0.10 | ) | $ | 0.19 | $ | 0.17 | ||||||
New orders |
$903 million | $2.50 billion | $2.21 billion |
Q1 FY 09 | Q1 FY 08 | Q4 FY 08 | ||||||||||
Non-GAAP net income (loss) |
($3 million) | $345 million | $264 million | |||||||||
Non-GAAP earnings (loss) per share |
$ | 0.00 | $ | 0.25 | $ | 0.20 |
Q1 FY 09 | Q1 FY 08 | Q4 FY 08 | ||||||||||||||||||||||||||||||||||
Operating | Operating | Operating | ||||||||||||||||||||||||||||||||||
New | Net | Income | New | Net | Income | New | Net | Income | ||||||||||||||||||||||||||||
(In millions) | Orders | Sales | (Loss) | Orders | Sales | (Loss) | Orders | Sales | (Loss) | |||||||||||||||||||||||||||
Silicon |
$ | 246 | $ | 546 | $ | 34 | $ | 1,075 | $ | 1,237 | $ | 445 | $ | 1,162 | $ | 744 | $ | 177 | ||||||||||||||||||
Applied Global
Services |
310 | 345 | 26 | 610 | 595 | 149 | 496 | 528 | 123 | |||||||||||||||||||||||||||
Display |
26 | 149 | 26 | 555 | 133 | 34 | 65 | 334 | 113 | |||||||||||||||||||||||||||
Energy and
Environmental
Solutions |
321 | 293 | (65 | ) | 260 | 122 | (48 | ) | 490 | 438 | 21 |
Three Months Ended | ||||||||
January 25, | January 27, | |||||||
(In thousands, except per share amounts) | 2009 | 2008 | ||||||
Net sales |
$ | 1,333,396 | $ | 2,087,397 | ||||
Cost of products sold |
941,820 | 1,152,416 | ||||||
Gross margin |
391,576 | 934,981 | ||||||
Operating expenses: |
||||||||
Research, development and engineering |
229,540 | 273,219 | ||||||
General and administrative |
141,241 | 115,976 | ||||||
Marketing and selling |
84,115 | 123,917 | ||||||
Restructuring and asset impairments |
132,772 | 48,986 | ||||||
Income (loss) from operations |
(196,092 | ) | 372,883 | |||||
Pre-tax loss of equity method investment |
15,808 | 9,586 | ||||||
Interest expense |
5,994 | 4,545 | ||||||
Interest income |
15,235 | 30,570 | ||||||
Income (loss) before income taxes |
(202,659 | ) | 389,322 | |||||
Provision (benefit) for income taxes |
(69,725 | ) | 126,946 | |||||
Net income (loss) |
$ | (132,934 | ) | $ | 262,376 | |||
Earnings (loss) per share: |
||||||||
Basic |
$ | (0.10 | ) | $ | 0.19 | |||
Diluted |
$ | (0.10 | ) | $ | 0.19 | |||
Weighted average number of shares: |
||||||||
Basic |
1,329,223 | 1,371,245 | ||||||
Diluted |
1,329,223 | 1,383,886 |
January 25, | October 26, | |||||||
(In thousands) | 2009 | 2008 | ||||||
ASSETS |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 1,366,196 | $ | 1,411,624 | ||||
Short-term investments |
551,196 | 689,044 | ||||||
Accounts receivable, net |
1,274,853 | 1,691,027 | ||||||
Inventories |
2,131,092 | 1,987,017 | ||||||
Deferred income taxes, net |
402,720 | 388,807 | ||||||
Income taxes receivable |
187,183 | 125,605 | ||||||
Other current assets |
366,428 | 371,033 | ||||||
Total current assets |
6,279,668 | 6,664,157 | ||||||
Long-term investments |
1,210,997 | 1,367,056 | ||||||
Property, plant and equipment |
2,888,267 | 2,831,952 | ||||||
Less: accumulated depreciation and amortization |
(1,780,081 | ) | (1,737,752 | ) | ||||
Net property, plant and equipment |
1,108,186 | 1,094,200 | ||||||
Goodwill, net |
1,171,740 | 1,174,673 | ||||||
Purchased technology and other intangible assets, net |
366,980 | 388,429 | ||||||
Equity method investment |
63,725 | 79,533 | ||||||
Deferred income taxes and other assets |
226,307 | 238,270 | ||||||
Total assets |
$ | 10,427,603 | $ | 11,006,318 | ||||
LIABILITIES AND STOCKHOLDERS EQUITY |
||||||||
Current liabilities: |
||||||||
Current portion of long-term debt |
$ | 1,259 | $ | 1,068 | ||||
Accounts payable and accrued expenses |
2,387,837 | 2,771,090 | ||||||
Income taxes payable |
140,635 | 173,394 | ||||||
Total current liabilities |
2,529,731 | 2,945,552 | ||||||
Long-term debt |
201,895 | 201,576 | ||||||
Other liabilities |
339,306 | 310,232 | ||||||
Total liabilities |
3,070,932 | 3,457,360 | ||||||
Stockholders equity: |
||||||||
Common stock |
13,293 | 13,308 | ||||||
Additional paid-in capital |
5,125,991 | 5,095,894 | ||||||
Retained earnings |
11,386,759 | 11,601,288 | ||||||
Treasury stock |
(9,157,868 | ) | (9,134,962 | ) | ||||
Accumulated other comprehensive loss |
(11,504 | ) | (26,570 | ) | ||||
Total stockholders equity |
7,356,671 | 7,548,958 | ||||||
Total liabilities and stockholders equity |
$ | 10,427,603 | $ | 11,006,318 | ||||
Three Months Ended | ||||||||
January 25, | January 27, | |||||||
(In thousands) | 2009 | 2008 | ||||||
Cash flows from operating activities: |
||||||||
Net income (loss) |
$ | (132,934 | ) | $ | 262,376 | |||
Adjustments required to reconcile net income (loss) to cash provided
by (used in) operating activities: |
||||||||
Depreciation and amortization |
71,228 | 78,474 | ||||||
Loss on fixed asset retirements |
3,447 | 11,211 | ||||||
Provision for bad debts |
47,526 | | ||||||
Restructuring and asset impairments |
132,772 | 48,986 | ||||||
Deferred income taxes |
(13,054 | ) | 3,417 | |||||
Net recognized loss on investments |
5,398 | 639 | ||||||
Pretax loss of equity-method investment |
15,808 | 9,586 | ||||||
Equity-based compensation |
33,608 | 38,722 | ||||||
Changes in operating assets and liabilities, net of amounts acquired: |
||||||||
Accounts receivable |
368,648 | 34,926 | ||||||
Inventories |
(144,075 | ) | (73,937 | ) | ||||
Other current assets |
10,890 | (22,579 | ) | |||||
Other assets |
1,311 | (4,984 | ) | |||||
Accounts payable and accrued expenses |
(518,373 | ) | (95,459 | ) | ||||
Income taxes |
(94,337 | ) | 94,248 | |||||
Other liabilities |
26,920 | 4,105 | ||||||
Cash provided by (used in) operating activities |
(185,217 | ) | 389,731 | |||||
Cash flows from investing activities: |
||||||||
Capital expenditures |
(73,318 | ) | (74,144 | ) | ||||
Cash paid for acquisition, net of cash acquired |
| (19,084 | ) | |||||
Proceeds from sales and maturities of investments |
541,689 | 2,038,001 | ||||||
Purchases of investments |
(227,348 | ) | (1,654,754 | ) | ||||
Cash provided by investing activities |
241,023 | 290,019 | ||||||
Cash flows from financing activities: |
||||||||
Debt borrowings |
510 | 343 | ||||||
Proceeds from common stock issuances |
182 | 15,681 | ||||||
Common stock repurchases |
(22,906 | ) | (600,000 | ) | ||||
Payment of dividends to stockholders |
(79,762 | ) | (83,068 | ) | ||||
Cash used in financing activities |
(101,976 | ) | (667,044 | ) | ||||
Effect of exchange rate changes on cash and cash equivalents |
742 | 221 | ||||||
Increase (decrease) in cash and cash equivalents |
(45,428 | ) | 12,927 | |||||
Cash and cash equivalents beginning of period |
1,411,624 | 1,202,722 | ||||||
Cash and cash equivalents end of period |
$ | 1,366,196 | $ | 1,215,649 | ||||
Supplemental cash flow information: |
||||||||
Cash payments for income taxes |
$ | 12,064 | $ | 41,878 | ||||
Cash payments for interest |
$ | 42 | $ | 45 |
Three Months Ended | ||||||||||||
January 25, | January 27, | October 26, | ||||||||||
(In thousands, except per share amounts) | 2009 | 2008 | 2008 | |||||||||
Non-GAAP Net Income (Loss) |
||||||||||||
Reported net income (loss) (GAAP basis) |
$ | (132,934 | ) | $ | 262,376 | $ | 231,095 | |||||
Equity-based compensation expense |
33,608 | 38,722 | 43,778 | |||||||||
Certain items associated with acquisitions 1 |
26,025 | 31,038 | 35,320 | |||||||||
Gain on sale of facility |
| | (21,837 | ) | ||||||||
Restructuring and asset impairments 2, 3, 4 |
132,772 | 48,986 | (9,686 | ) | ||||||||
Costs associated with ceasing development of
beamline implant products 5 |
| 1,021 | | |||||||||
Income tax effect of non-GAAP adjustments |
(62,939 | ) | (37,326 | ) | (14,765 | ) | ||||||
Non-GAAP net income (loss) |
$ | (3,468 | ) | $ | 344,817 | $ | 263,905 | |||||
Non-GAAP Net Income (Loss) Per Diluted Share |
||||||||||||
Reported net income (loss) per diluted share
(GAAP basis) |
$ | (0.10 | ) | $ | 0.19 | $ | 0.17 | |||||
Equity-based compensation expense |
0.02 | 0.02 | 0.02 | |||||||||
Certain items associated with acquisitions |
0.01 | 0.02 | 0.02 | |||||||||
Gain on sale of facility |
| | (0.01 | ) | ||||||||
Restructuring and asset impairments |
0.06 | 0.02 | | |||||||||
Costs associated with ceasing development
of beamline implant products |
| | | |||||||||
Non-GAAP net income (loss) per diluted share |
$ | 0.00 | $ | 0.25 | $ | 0.20 | ||||||
Shares used in diluted shares calculation |
1,329,223 | 1,383,886 | 1,350,092 |
1 | Incremental charges attributable to acquisitions consisting of inventory fair value adjustments on products sold and amortization of purchased intangible assets. | |
2 | Results for the first fiscal quarter ended January 25, 2009 included restructuring charges of $133 million associated with a restructuring program announced on November 12, 2008. | |
3 | Results for the first fiscal quarter ended January 27, 2008 included restructuring and asset impairment charges of $38 million associated with a global cost reduction plan and $11 million associated with ceasing development of beamline implant products. | |
4 | Results for the fourth fiscal quarter ended October 26, 2008 included a restructuring and asset impairment benefit of $9 million associated with a global cost reduction plan. | |
5 | Results for the fiscal quarter ended January 27, 2008 included other operating charges of $1 million associated with ceasing development of beamline implant products. |